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Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms that most commonly aﬀect the stomach or small intestine,
but can occur anywhere throughout the gastrointestinal tract. To the best of our knowledge, few cases have been reported in the
literature about the femur metastasis of GIST. This paper describes a metastasis of a gastrointestinal stromal tumour (GIST) to the
femur in a 62-year-old male, 2 years after treatment for a gastric primary. There were no signs of tumor recurrence at followup
after 12 mo. This case suggests that the femur can be a potential metastatic site of GIST.
1.Introduction
Gastrointestinal stromal tumour (GIST) is a rare disease.
The crude incidence rates of this soft tissue sarcoma are
1.5 individuals per 100,000 persons and year [1]. GIST
most commonly arises from the stomach and accounts for
about 1% of gastric malignancies [2]. Liver and peritoneal
metastatic lesions are often observed, but femur metastasis
is rarely found in GIST. Metastases are located intra-
abdominally in more than 90% [3]. There are few reports
about the femur metastasis of GIST in the literature. Here
we report one interesting GIST case with femur metastases 2
years after distal gastrectomy due to gastric GIST.
2. Report
Gastrointestinal stromal tumor (GIST) is the most common
mesenchymal tumor in the alimentary tract. Here we report
an unusual case of gastric GIST with femur metastasis. A
62-year-old man came to the clinic on January 16th, 2010,
complaining of his feeling of left thigh pain. X-ray demon-
strated the left femur pathologic fracture. He received distal
gastrectomy, perigastric lymphadenectomy in February 2008
for gastric GIST. Physical examination revealed a 4cm
thickening which was located in the left femur. Computed
tomography (CT) revealed an 8.5cm× 4cm× 3.5cm low
density mass (CT value = 69.7HU) (Figure 1). A complete
focus of tumor excision of the mass, bone graft, internal
ﬁxation was carried out for this patient on January 20th,
2010. Grossly, the surgical specimen consisted of a 9cm ×
4cm×3.5cmlarge,jelly,whitish-gray.Microscopically,itwas
conﬂuentandwasinﬁltratedwithspindlecells.Thesespindle
cells were predominantly arranged in interweaving fascicles
(Figure 2). Immunohistochemical stains demonstrated a
strong positivity for all c-kit (CD117), CD34, Vimentin, and
S-100 (Figure 3), which was consistent with the primary
tumor.Genesequenceanalysisshowedthatboththeprimary
tumors and the resected tumor harbored deletion mutations
aﬀecting codons 557/558 of exon 11 in the KIT. After the
operation, the patient took imatinib 400mg/d for 1 year.
And there was no sign of tumor recurrence during 12mo of
followup (Figure 4).
3. Discussion
GISTs are the most common mesenchymal tumours of the
gastrointestinal tract deﬁned by expression of c-KIT (CD





a GIST metastasis to the femur. The case we reported herein
is a high-grade GIST according to the Bucher grading system
[3]. Unlike gastric adenocarcinoma, femur metastasis of
GIST is unusual. In this case, perigastric lymphadenectomy
was performed and no metastasis was observed in all of 19
lymph nodes at the ﬁrst operation, no liver metastasis was
detected. With regards to a proposal on a recent histopatho-
logicalandprognostictumourclassiﬁcationofGIST,patients
with distant metastasis constitute a separate risk group. In
these cases, the size of the tumour and the mitotic index are
irrelevant factors in estimating crude survival [4]. It is likely
that some patients beneﬁt from resecting recurrent tumour
in cases with isolated local or metastatic disease, given the
c h a n c et or e s e c tt h i st u m o u rc o m p l e t e l y .T h eh i g hr a t eo f
local and distant tumour recurrence underlines the necessity
for additional therapies.
At present, surgery remains the mainstay of treatment in
GIST patients with isolated resectable GIST. Treatment with
imatinib was introduced for patients with metastatic disease
as an adjunct to surgery or in cases with nonresectable
tumour. The persistent use of imatinib was necessary for
this patient after complete resection of primary gastric and
metastatic GISTs. After his second operation, the patient
started imatinib treatment and survived without recurrence
till now. Imatinib proved to be eﬀective in terms of overall
survival and arrest of tumour progression [5, 6].
Inconclusion,GISTcaninvolvethefemurasametastatic
site and further studies are necessary to clarify the mecha-
nism of this metastasis.
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